AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
181.33
+1.69 (+0.94%)
At close: 4:04PM EST

181.33 0.00 (0.00%)
After hours: 5:47PM EST

Stock chart is not supported by your current browser
Previous Close179.64
Open180.87
Bid0.00 x 0
Ask0.00 x 0
Day's Range179.12 - 181.97
52 Week Range160.07 - 256.80
Volume4,043,473
Avg. Volume3,470,061
Market Cap60.307B
Beta1.09
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.80 (1.58%)
Ex-Dividend Date2017-11-16
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals9 hours ago

    Why this East Bay drug maker's stock price nearly doubled last year

    A new wrinkle to an old treatment helped an East Bay company nearly double its stock price as it moves toward a regulatory decision on its drug for removing "frown lines" between the eyebrows. While the long-term prospects of Revance Therapeutics Inc. (RVNC) may rest more with the billion-dollar potential of its drug as a longer-lasting alternative to Botox for erasing facial wrinkles, the company is lining up clinical trials testing its drug as a therapeutic against neck spasms, a common foot ailment and other non-aesthetic conditions. "We've got no shortage of indications," said Revance President and CEO Dan Browne.

  • Amgen/Allergan's Avastin Biosimilar Secures EU Approval
    Zacks11 hours ago

    Amgen/Allergan's Avastin Biosimilar Secures EU Approval

    Amgen (AMGN) and Allergan's Mvasi - a biosimilar version of Roche's cancer drug, Avastin - gets marketing approval in the EU.

  • Johnson & Johnson’s Revenue Estimates for 4Q17
    Market Realist12 hours ago

    Johnson & Johnson’s Revenue Estimates for 4Q17

    As we saw in Part 1 of this series, Johnson & Johnson (JNJ) is expected to report a 10.9% growth in revenue to $20.1 billion in 4Q17 compared to 4Q16. The above chart compares the actual revenues for Johnson & Johnson since 1Q16 and estimates for 4Q17. In 4Q17, the segment is expected to report growth in operating revenues, with a favorable impact from foreign exchange.

  • How Amgen’s Biosimilars Are Positioned for 2018
    Market Realist2 days ago

    How Amgen’s Biosimilars Are Positioned for 2018

    How Is Amgen Positioned for 2018?

  • TheStreet.com2 days ago

    Allergan Could Raise $1 Billion From Anti-Infectives Sale - RBC Capital Markets

    RBC Capital analysts argue Allergan could raise around $1 billion and send a "strong signal" on profitability with the sale of its anti-infectives business.

  • TheStreet.com2 days ago

    Allergan Needs More Time to Make a Proper Bottom

    The charts suggest that Allergan isn't going to accelerate any time soon.

  • GuruFocus.com2 days ago

    Polaris Global Value Fund 4th Quarter Shareholder Letter

    Review of markets and holdings

  • American City Business Journals2 days ago

    Judge approves settlement between Allergan shareholders and Ackman

    Bill Ackman’s $290 million settlement agreement with shareholders of drug developer Allergan plc has the support of a California federal judge. This is good news for the New York-based activist investor and Valeant Pharmaceuticals, as the two parties are being sued for insider trading. “The Court has vacated the trial date and indicated its preliminary approval of the settlement subject to submission of final papers and associated hearings,” Valeant said in a statement.

  • The Wall Street Journal3 days ago

    [$$] Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, Valeant

    A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed ...

  • Reuters3 days ago

    Imprimis receives FDA warning over eye medication advertising

    The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval. The Dec. 21 letter to San Diego-based Imprimis was posted on the FDA's website on Tuesday. Imprimis is contesting a lawsuit by rival Allergan Plc over allegations it is illegally selling and advertising unapproved drugs.

  • Teva's Trisenox Gets FDA Approval as First-Line Treatment
    Zacks3 days ago

    Teva's Trisenox Gets FDA Approval as First-Line Treatment

    Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

  • 1st trial date set in state lawsuit over opioid epidemic
    Associated Press7 days ago

    1st trial date set in state lawsuit over opioid epidemic

    OKLAHOMA CITY (AP) — The first trial date has been set for a lawsuit by a state against pharmaceutical companies over the opioid epidemic, according to Oklahoma's attorney general.

  • Morningstar8 days ago

    Concerns About Allergan's Health Are Overblown

    The stock price implies the worst-case scenario for this wide-moat company.

  • TheStreet.com8 days ago

    Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

    Healthcare executives meeting at JP Morgan Conference agree that new tax reform is good, but how it will impact the sector is not yet entirely clear.

  • MarketWatch8 days ago

    Ackman’s Pershing Square cuts hedge-fund fees due to lawsuit settlement

    Pershing Square Holdings, the hedge fund operated by noted activist investor Bill Ackman, on Wednesday announced it was slashing its management fees, a move related to the settlement of two class-action ...

  • What Analysts Recommend for Teva Pharmaceuticals
    Market Realist9 days ago

    What Analysts Recommend for Teva Pharmaceuticals

    Key Updates from Teva Pharmaceuticals at the Start of 2018

  • TheStreet.com9 days ago

    3 Reasons Allergan Is Set Up for Success in 2018

    Allergan's 2017 is mostly behind it, according to a UBS note Wednesday.

  • Treasury Bond Yield Pushes Ahead of the S&P 500
    InvestorPlace10 days ago

    Treasury Bond Yield Pushes Ahead of the S&P 500

    Also weighing was news overnight that the Bank of Japan had decide to taper its bond purchase program — a major sea change for a central bank that has really typified the extreme post-crisis money printing mentality. In the end, the Dow Jones Industrial Average gained 0.4%, the Nasdaq Composite gained 0.1%, the S&P 500 gained 0.1%, and the Russell 2000 broke the trend to fall 0.1%. Treasury bonds were hit hard, gold declined, and crude oil gained $1.64 to close at nearly $63-a-barrel.

  • Stocks Set for Record Run as Risks Multiply
    InvestorPlace10 days ago

    Stocks Set for Record Run as Risks Multiply

    Also weighing was news overnight that the Bank of Japan had decide to taper its bond purchase program — a major sea change for a central bank that has really typified the extreme post-crisis money printing mentality. At the industry level, auto and energy stocks led the way higher with gains of 1.8% and 1.5%, respectively.

  • Associated Press10 days ago

    Judge urges action on '100 percent manmade' opioid crisis

    COLUMBUS, Ohio (AP) — A federal judge on Tuesday set a goal of doing something about the nation's opioid epidemic this year, while noting the drug crisis is "100 percent man-made."

  • Reuters10 days ago

    U.S. pharma executives expect deals to pick up after tax overhaul

    The Trump administration's tax overhaul should accelerate major acquisitions by drugmakers in 2018 after a slow year for deals in 2017, according to senior executives from some of the largest pharmaceutical manufacturers. The $1.5-trillion bill, which U.S. President Donald Trump signed into law in December, lowers the income tax rate for U.S. companies to 21 percent from 35 percent, encourages them to repatriate cash, and modifies numerous deductions. Brent Saunders, chief executive officer of Allergan Inc (AGN.N), expects tax reform to finally clear the decks for big industry consolidation.

  • Allergan plc (NYSE:AGN): What Does The Future Look Like?
    Simply Wall St.10 days ago

    Allergan plc (NYSE:AGN): What Does The Future Look Like?

    Allergan plc’s (NYSE:AGN) released its most recent earnings update in September 2017, which showed company earnings became less negative compared to the previous year’s level – great news for investorsRead More...

  • Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected
    Zacks10 days ago

    Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected

    Allergan (AGN) announces weaker-than-expected sales outlook for 2018. A generic version of Restasis is expected to be launched in Q2.

  • Pershing Square lowering management fees
    CNBC Videos8 days ago

    Pershing Square lowering management fees

    CNBC's Leslie Picker reports on Pershing Square lowering its management fees to investors.